Rare & Orphan Lab · DeCure for X
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for acromesomelic dysplasia 2C, Hunter-Thompson type — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for acromesomelic dysplasia 2c, hunter-thompson type is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
bone morphogenetic protein receptor type 1B (BMPR1B) — BMPR1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 3MDY · 2.05 Å · ligand 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline (LDN). Experimental structure, not a prediction.
Acromesomelic dysplasia 2C, Hunter-Thompson type, is an autosomal recessive skeletal disorder that produces extremely short stature with shortening of the hands, feet, and middle segments of the limbs. A 1980 review of the radiographic features states that a diagnosis can be made in affected individuals older than six months, but provides no data on treatment or natural history beyond that age.
A 2018 study of a consanguineous Pakistani family identified a novel homozygous missense variant in BMPR1B (c.1190T > G, p.Met397Arg) that segregated with the Hunter-Thompson phenotype, with a LOD score of 3.9. This is the first report linking BMPR1B to this specific subtype. The study included no therapeutic intervention and no data on growth outcomes or functional measures.
A separate 2017 report on acromesomelic dysplasia Maroteaux type (a different subtype caused by NPR2 mutations) describes a single Taiwanese patient with a novel homozygous NPR2 mutation. That study also provides no treatment data. No abstract mentions any drug, growth factor, or surgical intervention for any form of acromesomelic dysplasia.
What is missing: any clinical trial, any tested therapy, any longitudinal data on growth or complication rates, and any patient stratification by genotype. No funding source has been committed to developing a treatment for this ultra-rare condition.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractThe radiographic features of acromesomelic dysplasia are presented, along with a summary of pertinent clinical features. They are thought to allow a diagnosis in affected individuals over six months of age. Since the condition has an autosomal recessive mode of genetic transmission and results in extremely short stature, the establishment of the diagnosis has practical importance.
https://doi.org/10.1148/radiology.137.2.7433666AbstractAcromesomelic dysplasia is genetically heterogeneous group of skeletal disorders characterized by short stature and acromelia and mesomelia of limbs. Acromesomelic dysplasia segregates in an autosomal recessive pattern and is caused by biallelic sequence variants in three genes (NPR2, GDF5, and BMPR1B). A consanguineous family of Pakistani origin segregating a subtype of acromesomelic dysplasia called Hunter-Thompson was clinically and genetically evaluated. Genotyping of microsatellite markers and linkage analysis revealed a 7.78 Mb homozygous region on chromosome 4q22.3, which harbors BMPR1B. Sequence analysis of the gene revealed a novel homozygous missense variant (c.1190T > G, p.Met397Arg) that segregates with the disease phenotype within the family and produced a Logarithm of odds (LOD) score of 3.9 with the disease phenotype. This study reports on the first familial case of acromesomelic dysplasia Hunter-Thompson type. It is also the first report of BMPR1B underlying the etiology of acromesomelic dysplasia Hunter-Thompson type.
https://doi.org/10.1111/ahg.12233AbstractAcromesomelic dysplasia Maroteaux type (AMDM) is a rare autosomal recessive skeletal disorder characterized by disproportionately short stature, predominantly affecting the acromesomelic sections of the limbs. AMDM results from a mutation in the natriuretic peptide receptor 2 (NPR2) gene, located on chromosome 9p13.3, and impairs skeletal growth.1
https://doi.org/10.1016/j.pedneo.2017.11.017Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
